Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis.
McGahan
L
L
The Canadian Coordinating Office for Health Technology Assessment, Canada. lyndam@ccohta.ca
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002170:Canada; D004059:Diffusion of Innovation; D016527:Drug Costs; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D014409:Tumor Necrosis Factor-alpha